21H7, >=98% (Hplc) | 217317-45-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 21H7, >=98% (Hplc)
• 英文别名: 6-bromo-N-[(2-hydroxyphenyl)methylideneamino]-2-methylquinoline-4-carboxamide
• CAS: 217317-45-8
• 化学式: C₁₈H₁₄BrN₃O₂
• 分子量: 384.232
• InChiKey: MTVVJOBPGQXHML-UHFFFAOYSA-N

物化性质

• 密度：
  1.49±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO：可溶5mg/mL，澄清（加热）

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• CULTIVATION OF PLACENTA TO ISOLATE EXOSOMES
  申请人：Celularity, Inc.

  公开号：EP3710575A1

  公开（公告）日：2020-09-23
• EXOSOMES FOR DISEASE TREATMENT
  申请人：Celularity Inc.

  公开号：EP3986381A1

  公开（公告）日：2022-04-27
• [EN] SALICYLIC ACID HYDRAZONES AS INHIBITORS OF THE ERK MAPKINASE PATHWAY AND FOR THE TREATMENT OF CANCER<br/>[FR] HYDRAZONES D'ACIDE SALICYLIQUE COMME INHIBITEURS DE VOIE D'ERK/ MAP KINASE ET POUR LE TRAITEMENT DU CANCER
  申请人：UNIV HEALTH NETWORK

  公开号：WO2006136008A1

  公开（公告）日：2006-12-28

  [EN] The present invention includes methods of using certain salicylic acid hydrazones as inhibitors of cancer cell proliferation and/or survival and/or clonogenic cancer cell proliferation and/or survival. In particular, the compounds of the invention are useful for treating ERK MAPkinase pathway-positive cell-proliferative disorders, such as cancer.
  [FR] Procédés d'utilisation d'hydrazones d'acide salicylique comme inhibiteurs de la prolifération et/ou de la survie des cellules cancéreuses et/ou de la prolifération et/ou de la survie des cellules cancéreuses clonogéniques. En particulier, les composés décrits sont utiles pour le traitement des troubles de prolifération cellulaire de type voie d'ERK/MAP kinase-positive, comme le cancer.
• [EN] EXOSOMES FOR DISEASE TREATMENT<br/>[FR] EXOSOMES POUR LE TRAITEMENT DE MALADIES
  申请人：CELULARITY INC

  公开号：WO2020257720A1

  公开（公告）日：2020-12-24

  The present invention provides method of treating diseases, disorders and conditions in a human subject comprising administering to the subject a population of exosomes or a composition comprising a population of exosomes, wherein said population of exosomes is positive for CD1c, CD20, CD24, CD25, CD29, CD2, CD3, CD8, CD9, CD11c, CD14, CD19, CD31, CD40, CD41b, CD42a, CD44, CD45, CD49e, CD4, CD56, CD62P, CD63, CD69, CD81, CD86, CD105, CD133-1, CD142, CD146, CD209, CD326, HLA-ABC, HLA-DRDPDQ, MCSP, ROR1, SSEA-4, or combinations thereof. Such diseases, disorders and conditions include lung, liver, central nervous system, kidney, cardiovascular, gastrointestinal, spleen, eye, systemic and ageing associated diseases, disorders, and conditions.